AGEN News
Agenus' Q3 Earnings Match Estimates, Revenues Miss Mark, Stock Down
AGEN's Q3 earnings meet estimates, but a revenue miss weighs on shares as pipeline progress, Armenian drug approvals and new funding emerge as key developments.
Zacks
Agenus' Q3 Earnings Match Estimates, Revenues Miss Mark, Stock Down
AGEN's Q3 earnings meet estimates, but a revenue miss weighs on shares as pipeline progress, Armenian drug approvals and new funding emerge as key developments.
Zacks
Agenus Reports More Than Half of Patients with Refractory MSS Metastatic Colorectal Cancer Achieved Long-Term Survival Following BOT+BAL Treatment at SITC 2026
Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced new findings from a long-term survivor analysis of its Phase 1b C-800-01 trial evaluating botensilimab (BOT), a multifunctional, Fc-enhanced anti-CTLA-4 antibody, in combination with balstilimab (BAL), an anti-PD-1...
Business Wire
Agenus (AGEN) Q3 Earnings Meet Estimates
Agenus (AGEN) delivered earnings and revenue surprises of 0.00% and -10.03%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Agenus Reports Third Quarter 2026 Results, Highlighted by First Marketing Authorizations for BOT+BAL and Global Investigator Support for Phase 3 ROBBIN Study
Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today reported financial results for the third quarter ended September 30, 2026, and highlighted progress preparing its global randomized Phase 3 ROBBIN trial of botensilimab (BOT), a multifunctional, Fc-enhanced anti-CTLA-4...
Business Wire
Agenus to Participate in Rodman & Renshaw Virtual Fireside Chat
Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that Robin Taylor, Chief Commercial Officer, and Zack Armen, Vice President of Corporate Development and Investor Relations, will participate in a virtual fireside chat hosted by Rodman & Renshaw on Thursday...
Business Wire
Agenus Announces Nature Medicine Publication of Multicenter UNICORN Phase 2 Trial Demonstrating Deep Responses with Neoadjuvant BOT+BAL in Resectable Colon Cancer
Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced the peer-reviewed publication of results from the investigator-sponsored, multicenter Phase 2 UNICORN trial evaluating short-course preoperative, or neoadjuvant, botensilimab (BOT), Agenus multifunctional...
Business Wire
Agenus Reports 72% of Patients with Locally Advanced dMMR Colon Cancer Had No Cancer Remaining at Surgery Following Six Weeks of BOT+BAL in Phase 2 NEOASIS Study at ESMO 2026
Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced early Phase 2 results from the mismatch repair-deficient (dMMR) colon cancer cohort of NEOASIS, an investigator-initiated pan-tumor study sponsored by the Netherlands Cancer Institute (NKI). NEOASIS is evaluating...
Business Wire
Agenus to Provide Third Quarter 2026 Financial Report and Development Update
Agenus Inc. (Agenus) (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that the Company will release its third quarter 2026 financial results before the market opens on Thursday, November 5, 2026. The earnings release will review Agenus recent progress in advancing...
Business Wire
Agenus to Participate in Chardans 10th Annual Healthcare Investor Conference
Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that Zack Armen, Head of Corporate Development and Investor Relations, will participate in a fireside chat and one-on-one investor meetings at Chardans 10th Annual Healthcare Conference: The Next 10 Years of...
Business Wire
Armenia Grants First Marketing Authorizations for Agenus BOT+BAL in Previously Treated MSS Metastatic Colorectal Cancer
Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that the Ministry of Health of the Republic of Armenia has granted marketing authorizations for Botvymo (botensilimab, BOT) and Evamplix (balstilimab, BAL), each approved for use in combination with the other for...
Business Wire